Synairgen plc - Lancet Respiratory Medicine publishes Phase 2 data
('Synairgen' or the 'Company')
Data from SG016 Phase II Clinical Trial published in Lancet Respiratory Medicine
- Data published in the peer-reviewed journal shows positive results for SNG001 in hospitalised COVID-19 patients
The double-blind, randomised, placebo-controlled trial assessed the efficacy and safety of inhaled SNG001 as a therapy for patients hospitalised with COVID-19. Patients were randomised (1:1) to receive SNG001 or placebo by inhalation via a mouthpiece once daily for 14 days. The primary endpoint was the change in clinical condition using the WHO Ordinal Scale for Clinical Improvement (OSCI) during the dosing period in the intention-to-treat population (ITT).
SNG001 was shown to be well tolerated and patients who received the drug had greater odds of improvement and recovered more rapidly. Patients receiving SNG001 had greater odds of improvement across the OSCI scale (OR 2·32; 95% CI: 1·07, 5·04; p=0·033) and were more likely to recover to "no limitation of activity" during treatment (HR 2·19; 95% CI: 1·03, 4·69; p=0·043). There were three deaths in the placebo group and none in the SNG001 group.
The full title of the publication is: "Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial", and can be accessed here.
For further enquiries, please contact:
Tel: + 44 (0) 23 8051 2800
Tel: + 44 (0) 20 7220 0500
Numis Securities Limited (Joint Broker)
Tel: +44 (0) 20 7260 1000
Consilium Strategic Communications (Financial Media and Investor
Tel: +44 (0) 20 3709 5700
Notes for Editors
Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Sir Stephen Holgate,
COVID-19, caused by the SARS-CoV-2 virus, is a global threat and there is an urgent need to assess new treatments to prevent and effectively treat the severe lower respiratory tract illness that can occur with this disease. Older people and those with co-morbidities such as heart and lung complications or diabetes are at greatest risk of developing severe or fatal disease.
Synairgen is currently recruiting into a trial of SNG001 in COVID-19 patients (over the age of 65, or those over 50 with a comorbidity) in the home setting. For more information about the trial please visit www.covidtrialathome.com.
Interferon beta applicability to COVID-19
Interferon beta ('IFN-beta') is a naturally-occurring protein, which orchestrates the body's antiviral responses. There is growing evidence that deficiency in IFN-beta production by the lung could explain the enhanced susceptibility in 'at-risk' patient groups to developing severe lower respiratory tract (lung) disease during respiratory viral infections. Furthermore, viruses, including coronaviruses such as SARS-CoV-2, have evolved mechanisms which suppress endogenous IFN-beta production, helping the virus to evade the innate immune system. The addition of exogenous IFN-beta before or during viral infection of lung cells in vitro either prevents or greatly reduces viral replication. Synairgen's SNG001 is a formulation of IFN-beta-1a for direct delivery to the lungs via nebulisation. It is pH neutral, and is free of mannitol, arginine and human serum albumin, making it suitable for inhaled delivery direct to the site of action. Phase I and II trial data have shown that SNG001 activates lung antiviral defences as measured in sputum cells, and that SNG001 has been well tolerated in approximately 280 asthma/COPD/COVID-19 patients to-date.
Quick facts: Synairgen PLC
Market Cap: -
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE